Your browser doesn't support javascript.
loading
PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: The GALA II Cohort.
Sherenian, M G; Cho, S H; Levin, A; Min, J-Y; Oh, S S; Hu, D; Galanter, J; Sen, S; Huntsman, S; Eng, C; Rodriguez-Santana, J R; Serebrisky, D; Avila, P C; Kalhan, R; Smith, L J; Borrell, L N; Seibold, M A; Keoki Williams, L; Burchard, E G; Kumar, R.
Afiliación
  • Sherenian MG; Division of Allergy-Immunology, Department of Pediatrics, Northwestern University, Chicago, IL, USA.
  • Cho SH; The Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
  • Levin A; Division of Allergy-Immunology, Department of Medicine, Northwestern University, Chicago, IL, USA.
  • Min JY; Division of Allergy-Immunology, Department of Internal Medicine, University of South Florida, Tampa, FL, USA.
  • Oh SS; Department of Public Health Science, Henry Ford Health System, Detroit, MI, USA.
  • Hu D; Department of Otolaryngology, Northwestern University, Chicago, IL, USA.
  • Galanter J; Department of Medicine, University of California, San Francisco, CA, USA.
  • Sen S; Department of Medicine, University of California, San Francisco, CA, USA.
  • Huntsman S; Department of Medicine, University of California, San Francisco, CA, USA.
  • Eng C; Division of Biostatistics, Department of Preventive Medicine, UTHSC, Memphis, TN, USA.
  • Rodriguez-Santana JR; Department of Medicine, University of California, San Francisco, CA, USA.
  • Serebrisky D; Department of Medicine, University of California, San Francisco, CA, USA.
  • Avila PC; Centro de Neumologia Pediatrica, CSP, San Juan, PR, USA.
  • Kalhan R; Pediatric Pulmonary Division, Jacobi Medical Center, Bronx, NY, USA.
  • Smith LJ; Division of Allergy-Immunology, Department of Medicine, Northwestern University, Chicago, IL, USA.
  • Borrell LN; Division of Pulmonary Medicine, Department of Medicine, Northwestern University, Chicago, IL, USA.
  • Seibold MA; Division of Pulmonary Medicine, Department of Medicine, Northwestern University, Chicago, IL, USA.
  • Keoki Williams L; Department of Health Sciences, Lehman College, CUNY, New York, NY, USA.
  • Burchard EG; Center for Genes, Environment and Health, National Jewish Health, Denver, CO, USA.
  • Kumar R; Department of Internal Medicine, Henry Ford Health System, Detroit, MI, USA.
Clin Exp Allergy ; 47(9): 1150-1158, 2017 Sep.
Article en En | MEDLINE | ID: mdl-28543872
BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma. OBJECTIVE: We sought to determine whether the association of a gain-of-function polymorphism in plasminogen activator inhibitor-1 (PAI-1) with airway obstruction is modified by asthma status, and whether any genotype effect persists after accounting for common exposures that increase PAI-1 level. METHODS: We studied 2070 Latino children (8-21y) with genotypic and pulmonary function data from the GALA II cohort. We estimated the relationship of the PAI-1 risk allele with FEV1/FVC by multivariate linear regression, stratified by asthma status. We examined the association of the polymorphism with asthma and airway obstruction within asthmatics via multivariate logistic regression. We replicated associations in the SAPPHIRE cohort of African Americans (n=1056). Secondary analysis included the effect of the at-risk polymorphism on postbronchodilator lung function. RESULTS: There was an interaction between asthma status and the PAI-1 polymorphism on FEV1 /FVC (P=.03). The gain-of-function variants, genotypes (AA/AG), were associated with lower FEV1 /FVC in subjects with asthma (ß=-1.25, CI: -2.14,-0.35, P=.006), but not in controls. Subjects with asthma and the AA/AG genotypes had a 5% decrease in FEV1 /FVC (P<.001). In asthmatics, the risk genotype (AA/AG) was associated with a 39% increase in risk of clinically relevant airway obstruction (OR=1.39, CI: 1.01, 1.92, P=.04). These associations persisted after exclusion of factors that increase PAI-1 including tobacco exposure and obesity. CONCLUSIONS AND CLINICAL RELEVANCE: The decrease in the FEV1 /FVC ratio associated with the risk genotype was modified by asthma status. The genotype increased the odds of airway obstruction by 75% within asthmatics only. As exposures known to increase PAI-1 levels did not mitigate this association, PAI-1 may contribute to airway obstruction in the context of chronic asthmatic airway inflammation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidor 1 de Activador Plasminogénico / Obstrucción de las Vías Aéreas / Mutación con Ganancia de Función Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Clin Exp Allergy Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidor 1 de Activador Plasminogénico / Obstrucción de las Vías Aéreas / Mutación con Ganancia de Función Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Clin Exp Allergy Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos